Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Volvisal
- Development stage
- Unknown
- Lead developer
- Yakult Honsha
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Volvisal is a trace element injection developed by Yakult Honsha for use in high-calorie parenteral nutrition (HPN). It provides essential trace elements—including iron (as ferric chloride), manganese (as manganese chloride), zinc (as zinc sulfate), copper (as copper sulfate), and iodine (as potassium iodide)—to patients receiving long-term intravenous nutrition to prevent deficiencies. These elements are vital for various enzymatic and metabolic processes. The product is indicated for the supplementation of trace elements in patients receiving high-calorie infusion. As of recent updates, Yakult Honsha has discontinued the product.
- Brand names
- Volvisalボルビサール注
- Other names
- Volvisal Injection
Beyond the preview
Go deeper on Volvisal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Volvisal.